Adverum Biotechnologies, a gene therapy company advancing novel medicines for serious rare and ocular diseases, has appointed Patrick Machado to its Board of Directors. Machado will be the Chair of the audit committee.
“Pat is an experienced board member and executive who has led finance, business development and legal functions for two decades at biopharmaceutical companies, spanning development to commercial stage,” said Paul Cleveland, executive Chai of the board.
“We look forward to benefitting from his energy and extensive background.”
Most recently, Machado was a co-founder of Medivation and served as its Chief Business Officer from 2009 to 2014; Chief Financial Officer from 2004 until his retirement in 2014; and as a member of its board of directors from April 2014 until its acquisition by Pfizer in September 2016.
From 1998 to 2001, Machado worked with ProDuct Health as Senior Vice President, Chief Financial Officer and earlier as general counsel.
Upon ProDuct Health’s acquisition by Cytyc Corporation, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002.
Earlier in his career, Machado worked for international law firm Morrison and Foerster and for the Massachusetts Supreme Judicial Court.
Machado received a JD from Harvard Law School and a BA and BS in German and Economics from Santa Clara University.
He also serves as a member of the board of directors at Armaron Bio, Chimerix, Inotek Pharmaceuticals, Roivant Sciences, and SCYNEXIS. At Chimerix and Inotek, Machado serves as a member of the audit committees.
